nivolumab,cabozantinib
bms
['nivo', 'cabozantinib', 'rcc,(-irccs),(-srcc),(-urcc)']
phase 2 trial with nivo + cabozantinib in metastatic non-clear cell rcc. high orr (47%) in patients with papillary histology #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer